REQUEST FOR A ESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)				
	in re Application	ď		
₩.				
	Application Num	ber	Fied	
	08/08	9, 407	7/8/93	
	Group Art Unit	Exeminer		
		<u>.L</u>		
Assistant Commissioner for Patents			per No	
Washington, DC 20231	•		0	
	•		्रिक् इ.स. इ.स.	
I hereby request access under 37 CFR 1.14(a)(3)(Iv) to the app	escation file reco	rd of the shove	
O application, which is	(CHECK ONE)		30	
(A) referred to in United States Patent No	umber 6,0	13, 432	_ column Face	
(B) referred to in an application that is on		dlan an ard fardh	15 47 655 A 44 15 53	
Application No	filed	·	on page of	
(C) an application that claims the benefit inspection, i.e., Application No	of the filing date of	f an application t	hat is open to public	
(D) an application in which the applicant I application to the public.				
Please direct any correspondence concerning	- 45-1 45 45	- f-11		
and a second concerning	d rurz reditest to ru	e tolkowing addit	ess:	
		•		
	-		<u> </u>	
111:00 Di				
Julian Livian	$-\frac{6}{7}$	/	·	
Michael hintan	,	/ Date		
Typed or printed name	•	FOR PTO US	EONLY	
- Inning liftlife	,	Approved by:		
		t leite	(Initials)	
		Unit:		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



United States Patent 1191

Luciw et al.

Patent Number: [11]

6,013,432

Date of Patent: [45]

Jan. 11, 2000

IMMUNOASSAY OF HIV ANTIBODIES USING RECOMBINANT OR SYNTHETIC SELECTED POL SEQUENCE

Inventors: Paul A. Luciw, Davis; Dino Dina, San Francisco, both of Calif.

[73] Assignee: Chiron Corporation, Emeryville, Calif.

[21] Appl. No.: 08/443,434

May 17, 1995 [22] Filed:

Related U.S. Application Data

Division of application No. 08/089,407, Jul. 8, 1993, which is a continuation of application No. 07/931,154, Aug. 17, 1992, which is a continuation of application No. 07/138,894, Dec. 24, 1987, Pat. No. 5,156,949, which is a continuationin-part of application No. 06/773,447, Sep. 6, 1985, abandoned, which is a continuation-in-part of application No. 06/696,534, Jan. 30, 1985, abandoned, which is a continuation-in-part of application No. 06/667,501, Oct. 31, 1984,

[51]	Int. Cl. ⁷	C12Q 1/70; G01N 33/53;
		G01N 33/569; C12N 15/48

[52] U.S. Cl. 435/5; 435/7.1; 435/7.92; 435/69.3; 435/287.1; 435/320.1; 435/960; 435/974; 530/300; 530/810; 530/806; 530/826;

435/69.3, 7.92, 287.1, 960, 974, 530/300, 810, 826, 806; 536/23.2

[56] References Cited

U.S. PATENT DOCUMENTS

Gallo .
Montagnier.
Levy.
Cosand 435/5

FOREIGN PATENT DOCUMENTS

10	ICLION I	THE IT DOCUMENTS
0 020 251	12/1980	European Pat. Off
0 060 057	9/1982	European Pat. Off
0 062 574	10/1982	European Pat. Off
0 073 635	3/1983	European Pat. Off
0 088 632	9/1983	European Pat. Off
0 116 201	8/1984	European Pat. Off
0 136 798	4/1985	European Pat. Off.
0 138 667	4/1985	European Pat. Off
0 139 216	5/1985	European Pat. Off
0 152 030	8/1985	European Pat. Off
0 165 120	12/1985	European Pat. Off
0 173 529	3/1986	European Pat. Off
0 178 978	4/1986	European Pat. Off
0 181 150	5/1986	European Pat. Off
0 185 444	6/1986	European Pat. Off
0 187 041	7/1986	European Pat. Off
0 201 540	11/1986	European Pat. Off
0 178 978	2/1992	European Pat. Off
2104902	3/1983	United Kingdom .
84/23659	9/1984	WIPO.
84/16013	10/1984	WIPO .
84/29099	11/1984	WIPO .
85/01473	1/1985	WIPO.
85/04897	11/1985	WIPO.
85/04903	11/1985	WIPO.

86/02383 4/1986 WIPO .

86/06414 11/1986 WIPO .

OTHER PUBLICATIONS

Allan et al., Science (1985) 228:1091-1094. Amann et al., Gene (1983) 25:167-178. Barin et al., Science (1985) 228:1094-1096. Beardsley et al., Nature (1984) 311:195. Bolivar et al., Gene (1977) 2:95-113. Brun-Vezinet et al., Lancet (1984) 1253-1256. Casadban et al., J. Bacteriology (1980) 143(2):971-980. Chanda et al., FASEB Proceedings (1985) 44(5):1540. Chang et al., J. Cell. Biochem. (1985) 9A: 81 Abstract 0187. Chang et al., Science (1985) 228:93-96. Chang et al., Nature (1985) 315:151-154. Chang et al., Bio/Technology (1985) 3(10):905-909. Chemical and Engineering News, (1984) p. 7. Chen et al., Nature (1984) 309:276-279. Chen et al., Nature (1983) 305:502-505. Chermann et al., in Gottlieb et al. (eds. 1984) "Acquired Immune Deficiency Syndrome" UCLA Symposia on Molecular Biology, News Series, vol. 16 (1984) pp. 31-46. Clinica, Abstract (1984) p. 9. De Boer et al., Proc. Natl. Acad. Sci. (1983) 80:21-25. DiMaio et al., Proc. Natl. Acad. Sci. (1982) 79:4030-4032. Dina et al., DNA (1985) 4(1):56. Ellrodt et al., Lancet (1984) 1:1383-1385. Fisher et al., Nature (1985) 316:262-265. Fischinger et al., Cancer Research (1985) 45:4694s-4699s. French, T.J., First Declaration of T.J. French (1994). Gallo et al., in Gottlieb et al. Eds. (1984) pp. 47-58 "Acquired Immune Deficiency Syndrome" UCLA Symposia on Molecular Biology, New Series (1984) 16:47-58. Gluzman et al., Cell (1981) 23:175-182. Gnann et al., J. Virology (1987) 61(8):2639-2641. Gray et al., Proc. Natl. Acad. Sci. (1982) 79:6598-6602. Groopman et al., New Eng. J. Med. (1984)

311(22):1419-1422.

Hahn et al., Nature (1984) 312:166-169.

Hattori et al., Virology (1984) 136:338-347.

Huang et al., DNA (1985) 4(1):70.

Karn et al., Meth. Enzymology (1983) 101:3-19.

Kitchen et al., Nature (1984) 312:367-369.

(List continued on next page.)

Primary Examiner-Michael P. Woodward Assistant Examiner-Mary K Zeman Attorney, Agent, or Firm-Dale H. Hoscheit; Alisa A. Harbin; Robert P. Blackburn

ABSTRACT

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

25 Claims, 59 Drawing Sheets